Self-assembling supramolecular dendrimer nanosystem for PET imaging of tumors

Philippe Garrigue\textsuperscript{a,b}, Jingjie Tang\textsuperscript{c}, Ling Ding\textsuperscript{c}, Ahlem Bouhlel\textsuperscript{e,b}, Aura Tintaru\textsuperscript{d}, Erik Laurini\textsuperscript{e}, Yuanyu Huang\textsuperscript{g,h}, Zhenbin Lyu\textsuperscript{a}, Mengjie Zhang\textsuperscript{d,g}, Samantha Fernandez\textsuperscript{e}, Laure Balasse\textsuperscript{e,b}, Wenjun Lan\textsuperscript{a}, Eric Mas\textsuperscript{a}, Domenico Marson\textsuperscript{a}, Yuhua Weng\textsuperscript{d,g}, Xiaoxuan Liu\textsuperscript{c}, Suzanne Giorgio\textsuperscript{c}, Juan Iovanna\textsuperscript{a}, Sabrina Prici\textsuperscript{h}, Benjamin Guillet\textsuperscript{b}, and Ling Peng\textsuperscript{c,1}

\textsuperscript{a}Aix-Marseille University, INSERM, INRA, Center de Recherche en Cardiovasculaire et Nutrition (C2VN), 13385 Marseille, France; \textsuperscript{b}Aix-Marseille University, Centre Européen de Recherche en Imagerie Médicale (CERIMED), 13005 Marseille, France; \textsuperscript{c}Aix-Marseille University, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), Equipe Labellisée Ligue Contre le Cancer, 13288 Marseille, France; \textsuperscript{d}Aix-Marseille University, CNRS, Institut de Chimie Radiculaire (ICR), 13013 Marseille, France; \textsuperscript{e}Molecular Biology and Nanotechnology Laboratory, Department of Engineering and Architecture, University of Trieste, 34127 Trieste, Italy; \textsuperscript{f}Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, Beijing 100081, China; \textsuperscript{g}School of Life Science, Beijing Institute of Technology, Beijing 100081, China; \textsuperscript{h}School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China; and \textsuperscript{i}Aix-Marseille University, INSERM, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), 13273 Marseille, France

Edited by Michael L. Klein, Temple University, Philadelphia, PA, and approved September 26, 2018 (received for review July 27, 2018)

Bioimaging plays an important role in cancer diagnosis and treatment. However, imaging sensitivity and specificity still constitute key challenges. Nanotechnology-based imaging is particularly promising for overcoming these limitations because nanosized imaging agents can specifically home in on tumors via the “enhanced permeation and retention” (EPR) effect, thus resulting in enhanced imaging sensitivity and specificity. Here, we report an original nanosystem for positron emission tomography (PET) imaging based on an amphiphilic dendrimer, which bears multiple PET reporting units at the terminations. This dendrimer is able to self-assemble into small and uniform nanomicelles, which accumulate in tumors for effective PET imaging. Benefiting from the combined dendrimeric multivalence and EPR-mediated passive tumor targeting, this nanosystem demonstrates superior imaging sensitivity and specificity, with up to 14-fold increased PET signal ratios compared with the clinical gold reference 2-fluorodeoxyglucose ([\textsuperscript{18}F]FDG). Most importantly, this dendrimer system can detect imaging-refractory low-glucose-uptake tumors that are otherwise undetectable using [\textsuperscript{18}F]FDG. In addition, it is endowed with an excellent safety profile and favorable pharmacokinetics for PET imaging. Consequently, this dendrimer nanosystem constitutes an effective and promising approach for cancer imaging. Our study also demonstrates that nanotechnology based on self-assembling dendrimers provides a fresh perspective for biomedical imaging and cancer diagnosis.

Significance

Nanotechnology-based imaging is expected to bring breakthroughs in cancer diagnosis by improving imaging sensitivity and specificity while reducing toxicity. Here, we developed an innovative nanosystem for positron emission tomography (PET) imaging based on a self-assembling amphiphilic dendrimer. This dendrimer assembled spontaneously into uniform supramolecular nanomicelles with abundant PET reporting units on the surface. By harnessing both dendrimeric multivalence and the “enhanced permeation and retention” (EPR) effect, this dendrimer nanosystem effectively accumulated in tumors, leading to exceedingly sensitive and specific imaging of various tumors, especially those that are otherwise undetectable using the clinical gold reference 2-fluorodeoxyglucose ([\textsuperscript{18}F]FDG). This study illustrates the power of nanotechnology based on self-assembling dendrimers to provide an effective platform for bioimaging and related biomedical applications.

Author contributions: P.G., Y.H., J.I., S.P., B.G., and L.P. designed research; P.G., J.T., L.D., A.B., A.T., E.L., Y.H., Y.W., X.L., S.G., B.G., and L.P. analyzed data; and P.G., J.T., L.D., A.B., A.T., E.L., Z.L., M.Z., S.F., L.B., W.L., E.M., D.M., and S.G. performed research; J.T. and L.P. wrote the paper.

Additional contributors: A.B. contributed new reagents/analytic tools; P.G., J.T., L.D., A.B., A.T., E.L., Y.H., Y.W., X.L., S.G., B.G., and L.P. analyzed data; and P.G., S.P., B.G., and L.P. wrote the paper.

Published online October 22, 2018.
oncologic imaging mainly because of its excellent sensitivity up to the femtomolar range, with quantitative imaging capabilities and limitless depth of penetration (12, 13). Moreover, hybrid cameras enable precise anatomic localization of PET functional imaging via coregistration with X-ray computed tomography (CT) (14). In this study, we selected gallium-68 $^{68}$Ga as the high-energy positron-emitter radioisotope because it is an interesting and common PET radiotracer with a physical half-life of 68 min, a time long enough for imaging acquisition yet short enough for safe radioprotection of both patients and medical staff (15). In addition, generation of clinically used radioactive $^{68}$Ga(III) can be conveniently achieved using homemade facilities for on-demand production via a $^{68}$Ge/$^{68}$Ga generator. It should be noted that a chelator is required to enable stable $^{68}$Ga(III) radiolabeling for PET imaging (16). We therefore opted for 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) as the Ga(III) chelator because of its advantages over the commonly used $^{1}$,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). In fact, NOTA chelates Ga(III) with superior thermodynamic stability and kinetic inertness (17) than DOTA, thanks to the perfect match of size, geometry, and denticity between the NOTA macrocycle and the small radionuclide Ga(III). This, in turn, is reflected in favorable enthalpic and entropic contributions to the chelation (18).

Also, NOTA is able to complex Ga(III) rapidly and efficiently at room temperature and has high stability in vivo (16, 19). Given the large size of the NOTA macrocycle, to avoid eventual synthetic difficulty (20–22) and instability stemming from possible steric congestion of the dendrimer terminals, we chose to focus on the lowest generation amphiphilic dendrimer 1, which bears four NOTA terminals and one hydrophobic alkyl chain (Fig. 1). This small amphiphilic dendrimer can indeed self-assemble into stable and uniform nanomicelles, which effectively accumulate in tumors via the EPR effect, leading to specific and sensitive imaging of tumors. Most importantly, this dendrimer nanosystem is able to detect, with exceedingly high signal-to-noise ratios, the imaging-refractory low–glucose-uptake tumors that are otherwise difficult to image using the clinical gold reference 2-fluorodeoxyglucose ($^{18}$F]FDG). This original supramolecular imaging system based on self-assembling amphiphilic dendrimer therefore constitutes a promising nanoplatform for cancer imaging and detection.

---

Fig. 1. Schematic illustration of the supramolecular dendrimer nanosystem, based on a self-assembling amphiphilic dendrimer bearing radionuclide terminals, for positron emission tomography (PET) imaging of tumors.

Fig. 2. Synthesis of the amphiphilic dendrimer 1 and its chelation with the nonradioactive isotope $^{69}$GaGa$^{3+}$ at the terminals. (A) Synthesis scheme: (i) (a) NODA-Ga(tBu)$_3$, PyBOP, NMM, DMF, 30 °C, 72 h; (b) TFA, CH$_2$Cl$_2$, 30 °C, 16 h. (ii) $^{69}$GaGaCl$_3$, 1.0 M HCl, 20 °C, 15 min. (B) High-resolution mass spectrum showing the isotopic pattern characteristic of the triply charged species $[^{69}$GaGa$+3H]^3+$. The Inset shows the calculated isotopic pattern. (C) Isothermal titration calorimetry (ITC) curve for chelation of Ga$^{3+}$ with dendrimer 1. The Inset shows measured heat power versus time elapsed during titration.
Results and Discussion
Amphiphilic Dendrimer 1 Bearing NOTA Terminals Is Able to Complex with Ga(III) and Self-Assemble into Small and Uniform Nanomicelles.

The NOTA-bearing dendrimer 1 devised for PET imaging in this work was synthesized starting with the amine-terminated amphiphilic dendrimer, which was conjugated with the reagent NODA-GA(tBu)_3, followed by subsequent deprotection. The dendrimer 1 was obtained with an excellent overall yield of 83% (Fig. 2A and SI Appendix, Scheme S1B), and its chemical structure was confirmed using ^1H, ^13C, and 2D NMR and high-resolution mass spectrometry (HRMS), which revealed the characteristic signals corresponding to the chemically conjugated NOTA entities (SI Appendix, Figs. S1 and S2A). The characteristic signals for NOTA moieties in 1 could not be observed when simply mixing the amine-terminating dendrimer with the NOTA reagent in the absence of the coupling agent. This indicates the successful covalent conjugation of the NOTA functionality on the dendrimer terminals. Chelation of the isotope ^69Ga^3+ by 1 using ^69GaCl_3 (Fig. 2A and SI Appendix, Scheme S1B), followed by dialysis to remove free ^69Ga^3+, yielded the non-radioactive dendrimer [^69Ga]Ga-1. HRMS showed the isotopic pattern characteristic of the triply charged species [[^69Ga]Ga-1+3H]^{3+} in addition to the molecular weight peak (Fig. 2B and SI Appendix, Fig. S2B), confirming the successful complexation of four ^69Ga(III) ions within the dendrimer 1. Since ^69Ga^3+ possesses a quadrupolar moment and very low NMR sensitivity (23), well-resolved NMR spectra for [^69Ga]Ga-1 could not be obtained. We therefore further studied [^69Ga]Ga-1 using isothermal titration

Fig. 3. Self-assembling of the amphiphilic dendrimer [^68Ga]Ga-1 into small and uniform nanomicelles. (A) Dynamic light scattering (DLS) measurement, (B) transmission electron microscopy (TEM) image, and (C–E) computer modeling of the self-assembled nanostructures formed by [^68Ga]Ga-1. (C) Final image of the [^68Ga]Ga-1 self-assembly process into spherical micelles as obtained from atomistic molecular-dynamics (MD) simulations. Different parts of the [^68Ga]Ga-1 molecules are represented as spheres (atom color: gray, hydrocarbon chain; lavender, NOTA cage; hot pink, Ga^3+), while water molecules are shown as water transparent spheres. The first water shell surrounding each molecule/micelle is highlighted as a dark water transparent contour. (D) Zoomed image of a [^68Ga]Ga-1 micelle as extracted from the equilibrated portion of the MD trajectory. Colors as in C. Water molecules are not shown for clarity. (E) Radial distribution function of the Ga(III)-bearing terminals as a function of the distance from the center of mass of the [^68Ga]Ga-1 micelles.

Fig. 4. Radiolabeled dendrimer [^68Ga]Ga-1 for PET imaging of various tumors. Tumor targeting and uptake assessment of [^68Ga]Ga-1 in mouse ectopic xenograft models of (A) prostate adenocarcinoma (22Rv1 cell line), (B) glioma (U87 cell line), (C) colorectal adenocarcinoma (HT-29 cell line), and (D) pancreatic adenocarcinoma (SOJ-6 cell line), in comparison with [^18F]FDG, the clinical gold reference for PET imaging in oncology. (Top) Representative examples of PET images. The orange arrows indicate tumor positions. (Middle) Quantifications from PET images of tumor uptake expressed as mean ± SD percentage injected dose per gram (n = 3; except for 22Rv1, n = 4; *P ≤ 0.05, Kruskal–Wallis test). (Bottom) Quantifications from PET images of tumor-to-background ratios (right forelimb biceps muscle taken as background reference). All data were expressed as mean ± SD percentage (n = 3; *P ≤ 0.05, Kruskal–Wallis test).
Fig. 5. EPR-based tumor uptake of $^{68}$Ga-Ga-I for excellent PET imaging. Comparison of the tumor accumulation of the dendrimer nanosystem $^{68}$Ga-Ga-I, the small molecular complex $^{68}$Ga-Ga-NOTA, and the clinical reference $^{18}$F-FDG in ectopic (A) SOJ6- and (B) LIPC-xenografted mice as well as in (C) orthotopic SOJ6-xenografted mice. (Top) Representative examples of $^{18}$F-FDG (Left), $^{68}$Ga-Ga-NOTA (Middle), and $^{68}$Ga-Ga-I (Right) PET images. The orange arrows indicate tumor positions. (Middle) Quantifications from PET images of tumor uptake, expressed as mean ± SD percentage injected dose per gram (n = 3; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001, Kruskal–Wallis test). (Bottom) Quantifications from PET images of tumor-to-background ratios (right forelimb biceps muscle taken as background reference), expressed as mean ± SD percentage (n = 3; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001, Kruskal–Wallis test). (D) Correlation between $^{68}$Ga-Ga-I PET signal in tumors and tumor blood flow assessed by 3D-Doppler (percentage) in orthotopic SOJ6-xenografted mice (n = 3; two time points; Pearson correlation $R^2 = 0.751$, *P = 0.0255).

colorimetry (ITC) (Fig. 2C), which demonstrated the spontaneous formation of the $^{68}$Ga-Ga-I complex ($\Delta G = -6.99$ kcal/mol), resulting from the balanced and favorable contributions of both the enthalpic ($\Delta H = -4.05$ kcal/mol) and the entropic component ($-T\Delta S = -2.94$ kcal/mol). Finally, the molar ratio identified by the ITC-derived number of occupied sites (n = 3.9) (Fig. 2C) confirms the 4:1 stoichiometry for each $^{68}$Ga-Ga-I complex as derived from the HRMS analysis described above. All of these results substantiate the practical and reliable synthesis of amphiphilic dendrimers bearing either NOTA terminal or Ga$^{3+}$-chelated NOTA terminals.

Having the Ga$^{3+}$-chelated NOTA-terminating dendrimer $^{68}$Ga-Ga-I at hand, we studied its self-assembling properties. Although $^{68}$Ga-Ga-I is highly soluble in water (≥10 mg/mL), it self-assembles in water with a critical micelle concentration (CMC) of 64 ± 1 μM. We also assessed the octanol-water partition coefficient of $^{68}$Ga-Ga-I (log P), with the P value being −140 ± 17. This indicates that the $^{68}$Ga-Ga-I nanoparticles are hydrophilic, an advantageous feature for bioimaging. Dynamic light scattering (DLS) analysis also revealed that $^{68}$Ga-Ga-I formed small nanoparticles with average dimensions around 14 nm (Fig. 3A), a typical size for nanomicelles. The formed nanoparticles were stable and maintained similar size up to 1 wk (SI Appendix, Fig. S3). The effective formation of $^{68}$Ga-Ga-I nanomicelles was further confirmed by transmission electron microscopy (TEM) imaging, which showed small and spherical nanoparticles (Fig. 3B). We also examined the formation of $^{68}$Ga-Ga-I nanomicelles using atomic molecular-dynamics (MD) simulations (24, 25). We observed that, during the timescale of the MD course (1.0 μs), the randomly distributed $^{68}$Ga-Ga-I complexes spontaneously aggregate into spherical micelles (Fig. 3C and D) with an effective average radius of 6.9 ± 0.2 nm. Accordingly, the corresponding average $^{68}$Ga-Ga-I micelle diameter of 13.8 nm is in excellent agreement with the experimental value obtained from DLS and TEM (Fig. 3A and B). Further examination of the conformational structures of the formed nanomicelles (Fig. 3D) and the radial distribution of the terminal functions (Fig. 3E) revealed that the terminals bearing the Ga(III) functions are all located on the micellar periphery, and no backfolding was observed. Collectively, the structural and physicochemical properties exhibited by these self-assembled nanomicelles make them ideal candidates for nanotechnology-based imaging purposes, as presented below.

Radionuclide $^{68}$Ga-Labeled Dendrimer Facilitates Excellent PET Imaging of Tumors. Motivated by the favorable self-assembling properties of $^{68}$Ga-Ga-I, we prepared the corresponding radioactive dendrimer $^{68}$Ga-Ga-I for PET imaging. Using freshly generated $^{68}$Ga-GaCl$_3$, the $^{68}$Ga-Ga-I complex was obtained with a radiochemical purity of 91.9 ± 2.3% soon after synthesis (SI Appendix, Fig. S4A). In addition, radiolabeling was stable up to 2 h after synthesis at room temperature and at 37 °C, both in 0.9% NaCl solution and in human serum (SI Appendix, Fig. S4B). The $^{68}$Ga-Ga-I complex therefore satisfies the two important prerequisites for PET imaging, namely, high radiochemical purity and stability.

We then carried out PET imaging using the self-assembled nanomicelles of $^{68}$Ga-Ga-I to quantify their tumor targeting and uptake in various xenograft mouse models of cancer, including human prostate carcinoma (22Rv1 cell line; Fig. 4A), human glioblastoma (U87 cell line; Fig. 4B), human colorectal adenocarcinoma (HT-29 cell line; Fig. 4C), and human pancreatic adenocarcinoma (SOJ-6 cell line; Fig. 4D). In almost all cases, the observed effective tumor uptake and tumor-to-background ratios with $^{68}$Ga-Ga-I were superior to those obtained with $^{18}$F-FDG,
the clinical gold reference for PET imaging in oncology (Fig. 4). $[^{18}]$FDG PET is based on the high consumption of glucose needed by the fast proliferating and nutrient-greedy cancer cells, and the major drawback of $[^{18}]$FDG is its physiological accumulation in tissues with high glucose consumption, like myocardium and brain (26), which increases the background signal and has a negative impact on the image quality. It should also be mentioned that certain tumors have low $[^{18}]$FDG uptake, including tumors derived from human glioblastoma U87 cells and human pancreatic adenocarcinoma SOJ-6 cells. Remarkably, our $[^{68}]$Ga-Ga-I nanoparticles had no preferential accumulation in the brain and a low uptake in the heart in all cases. Also, $[^{68}]$Ga-Ga-I successfully imaged tumors with both high and low $[^{18}]$FDG uptake, and the PET signal ratios were up to 14-fold higher with $[^{68}]$Ga-Ga-I nanoparticles than with $[^{18}]$FDG (Fig. 4). Therefore, we reasoned that the difference in $[^{18}]$FDG and $[^{68}]$Ga-Ga-I nanoparticle-based imaging could be ascribed to different tumor uptake mechanisms, with EPR-based tumor accumulation being the most plausible one for the uptake of $[^{68}]$Ga-Ga-I.

**EPR-Based Tumor Uptake of $[^{68}]$Ga-Ga-I for Effective PET Imaging.** To investigate the uptake mechanism and obtain evidence for the EPR-based tumor accumulation of $[^{68}]$Ga-Ga-I, we carried out a comparative study of PET imaging for tumor detection using the dendrimer nanosystem $[^{68}]$Ga-Ga-I and the small molecular complex $[^{68}]$Ga-Ga-NOTA (SI Appendix, Scheme S1A) in three pancreatic cancer models, namely, ectopic SOJ6- and LIPC-xenografted mice (Fig. 5 A and B) and an orthotopic pancreatic xenograft mouse (Fig. 5C). $[^{18}]$FDG was used as the reference control in all studies. Coregistration with CT enabled precise, anatomical localization of PET signals for further quantification in tumors. The overall excellent tumor-to-background ratios highlighted the high quality of images and tumor targeting obtained with the $[^{68}]$Ga-Ga-I nanosystem. Indeed, the tumor uptake of the $[^{68}]$Ga-Ga-I nanoparticles was significantly higher than that of the simple $[^{68}]$Ga-Ga-NOTA complex and the clinical reference $[^{18}]$FDG (up to 100-fold increase) not only in the two ectopic pancreatic cancer mouse models (Fig. 5 A and B) but also in the orthotopic pancreatic cancer model (Fig. 5C). Moreover, we observed a significant negative correlation between the tumor uptake of $[^{68}]$Ga-Ga-I and tumor blood flow as measured by 3D-Doppler (Fig. 5D). This suggests that $[^{68}]$Ga-Ga-I is more likely to accumulate in low-turbulent blood flow tumors, where the EPR effect contribution takes effect (27, 28). These results demonstrated that the significantly enhanced tumor uptake and the resulting superior imaging quality of $[^{68}]$Ga-Ga-I indeed stem from the nanoparticle-based EPR effect of the tumor microenvironment, which is distinctly different from the uptake mechanism of $[^{18}]$FDG. The different uptake mechanisms of $[^{68}]$Ga-Ga-I and $[^{18}]$FDG mean that these two agents can be used in a complementary manner for tumor imaging, with $[^{68}]$Ga-Ga-I offering superior imaging, especially for the tumors that are otherwise undetectable using the clinical reference $[^{18}]$FDG.

**Advantageous Pharmacokinetics and Safety Profile of $[^{68}]$Ga-Ga-I for PET Imaging.** Encouraged by these promising PET imaging results of $[^{68}]$Ga-Ga-I, we further studied the pharmacokinetics and biodistribution of $[^{68}]$Ga-Ga-I in the orthotopic xenograft mice using μPET dynamic acquisitions (Fig. 6). This allowed us to trace and quantify the distribution of $[^{68}]$Ga-Ga-I across body organs from 5 min up to 2 h postinjection. Unlike drug delivery procedures, which require a constant supply of drug to the target tissue, bioimaging demands a rather rapid and intense accumulation of the imaging agent within tumor lesions and a fast clearance of the nonspecific, nonfixed radiotracer. By virtue of its distinct nanostructure, $[^{68}]$Ga-Ga-I has a biological elimination half-life of 171 ± 42 min, as obtained from pharmacokinetic analysis of $[^{68}]$Ga-Ga-I in blood samples (SI Appendix, Fig. S5). This biological half-life of $[^{68}]$Ga-Ga-I is particularly advantageous for PET imaging, as it allows effective image capture shortly after its administration (29, 30). This feature, coupled with the short physical half-life of $[^{68}]$Ga-Ga-I (68 min), allows for both rapid and optimal imaging and fast elimination of radioactivity from the body. Further studies showed that the uptake of $[^{68}]$Ga-Ga-I in tumors was steadily increased, while that in the liver was significantly decreased within the 2-h imaging period (Fig. 6). This finding is also in line with the characteristic size and charge features of the $[^{68}]$Ga-Ga-I nanoparticles. Indeed, their nanosize allowed them to be readily trapped and enriched in the tumor via the EPR effect, and in the liver through the renal clearance of nanoparticles (31). This resulted in superior imaging quality of $[^{68}]$Ga-Ga-I, which is distinctly different from the uptake mechanism of $[^{18}]$FDG. The combination of high tumor signal stemming from the EPR effect, short biological half-life, and the absence of accumulation in most of the organs except the liver, all contribute to the favorable pharmacokinetic properties of the $[^{68}]$Ga-Ga-I nanoparticles for PET imaging of tumors.

It should be mentioned that, during the experimental period, the mice receiving $[^{68}]$Ga-Ga-I did not show any abnormal behavior or adverse effects. Healthy mice administered with $[^{68}]$Ga-Ga-I showed no cytokine induction, neither blood biochemistry defects nor organ damage, even when the administered dose of $[^{68}]$Ga-Ga-I was 10 times higher than the PET imaging dose (SI Appendix, Figs. S6–S8). These results confirm that $[^{68}]$Ga-Ga-I is devoid of toxic effects while delivering superior PET imaging quality.
Conclusions

In this work, we have established an effective and excellent self-assembling supramolecular dendrimer nanosystem capable of EPR-based tumor accumulation and PET imaging in various ectopic and orthotopic tumor-xenograft mouse models. Remarkably, the obtained PET images showed significantly higher quality in terms of sensitivity, specificity, and accuracy compared with the clinical reference [18]F-FDG and the small molecular [18]Ga Ga-NOTA complex. Most importantly, this dendrimer system can detect imaging-refractory low-glucose-uptake tumors that are otherwise undetectable using [18]F-FDG. In addition, it is endowed with an excellent safety profile and favorable pharmacokinetics for PET imaging, highlighting its potential application for tumor imaging. It is also noteworthy that, until now, there has been no PET nanotracer currently available in oncology, although several have entered in clinical trials (31–33). It will be interesting to compare our dendrimer nanosystem with these reported PET nanotracers to further validate its imaging performance and potential for clinical translation. We will strive in our efforts in this direction.

It is important to note that the results reported in this study provide evidence that self-assembling dendrimer nanosystems hold promise as robust platforms for the delivery of agents in biomedical imaging. These nanosystems can potentially be extended to other imaging modalities such as single-photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI) as well as to combined imaging–therapy applications such as those based on radiotherapy and imaging with the radionuclide [18]F-FDG. The possibility of controlling the chemistry, the size, and the hydrophobicity–hydrophilicity balance of amphiphilic dendrimers (7, 9, 34) provides us with a unique opportunity to fine-tune the self-assembling feature to create functional supramolecular nanosystems for on-demand delivery of different imaging and therapeutic agents for a diverse range of imaging modalities and combined imaging–therapy applications (8, 35, 36). This will offer a particularly interesting perspective on the design and construction of tailor-made self-assembling dendrimer nanosystems for various biomedical applications in general.

Materials and Methods

A full description of the materials and methods is provided in the SI Appendix, including preparation and characterization of 1, [18]GaGa-1, [18]GaGa-NOTA, and [18]GaGa-1, as well as PET imaging of different xenograft mice along with the pharmacokinetics and toxicity evaluation. These include NMR, HRMS, TEM, DLS, CMC, ITC, computer modeling, radiolabeling, cell culture, animal xenograft, PET/CT imaging, biodistribution, blood biochemistry, immunotoxicity, and histopathological analysis. Additional figures include synthesis and characterization of 1 and [18]GaGa-1 (SI Appendix, Figs. 51 and 52 and Scheme 51), nanoparticle stability, radiolabeling purity and stability of [18]GaGa-1 (SI Appendix, Figs. 53 and 54), biodistribution (SI Appendix, Figs. 55), cytokine induction and serum biochemistry as well as histopathological analysis of main organs (SI Appendix, Figs. 56–58) of mice treated with 1 and [18]GaGa-1. All procedures involving animals were performed in accordance with protocols approved by the Institution’s Animal Care and Use Committees at Aix-Marseille University or Peking University.

ACKNOWLEDGMENTS. We thank Advanced Accelerator Applications (Marcello) for [18]F-FDG, and Michel Skandalovski (Centre Européen de Recherche en Imagerie Médicale, Aix-Marseille University) and Marie Nollet (Centre de Recherche Cardiovasculaire et Nutrition, Aix-Marseille University) for technical support. We are grateful to Fondation de l’Avenir, La Ligue Nationale Contre le Cancer (L.P. and Z.L.), EuroNanoMed II Grants ANR-15-EMNZ-0006-02 and ANR-16-EMNZ-0004-02 (to L.P.), Beijing Institute of Technology (Y.H.), Central Universities (Y.H.), Hunan Provincial Natural Science Foundation of China Grant 2018J1019 (to Y.H.), Huixiang Young Talent Program Grant 2018RS3094 (to Y.H.), and Italian Association for Cancer Research Grant IG17413 (to S.P.) for financial support. J.T., L.D., and W.L. are supported by the China Scholarship Council.

1. Chow EK-H, Ho D (2013) Cancer nanomedicine: From drug delivery to imaging. Sci Transl Med 5:216rv.
2. Li C (2014) A targeted approach to cancer imaging and therapy. Nat Mater 13: 110–115.
3. Moea H, Wu J, Sawia T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 65:271–284.
4. Shi J, KantoFF PW, Wooster R, Farokhzad OC (2017) Cancer nanomedicine: Progress, challenges and opportunities. Nat Rev Cancer 17:20–37.
5. Chaouah VP, Jain RK (2013) Strategies for advancing cancer nanomedicine. Nat Mater 12:958–962.
6. Lehn JM (2002) Toward self-organization and complex material. Science 295:2400–2403.
7. Percec V, et al. (2010) Self-assembly of Janus dendrimers into uniform dendrimeromes and other complex architectures. Science 328:1009–1012.
8. Wu T, et al. (2015) Anticancer drug nanosomies formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance. Proc Natl Acad Sci USA 112: 2978–2983.
9. Sherman SE, Xiao Q, Percec V (2017) Mimicking complex biological membranes and their programmable glycan ligands with dendrimersomes and glycodendrimersomes. Chem Rev 117:6538–6631.
10. Liu X, et al. (2014) Adaptive amphiphilic dendrimer-based nanoassemblies as robust and versatile sRNA delivery systems. Angew Chem Int Ed Engl 53:11822–11827.
11. Chen C, et al. (2016) Mastering dendrimer self-assembly for efficient sRNA delivery: From conceptual design to in vivo efficient gene silencing. Small 12:3667–3676.
12. Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683–693.
13. James MS, Gambhir SS (2012) A molecular imaging primer: Modalities, imaging agents, and applications. Physiol Rev 92:897–965.
14. Beyer T, Townsend DW, Czemaj J, Freudenberg LS (2011) The future of hybrid imaging part 2: PET/CT. Insights Imaging 2:225–234.
15. Cutler CS, Henriksen HM, Siyav N, Huclier-Markai S, Jurisson SS (2015) Radiolabels for combined imaging and therapy. Chem Rev 115:858–883.
16. Wadas TJ, Wong EH, Weisman GR, Anderson CJ (2010) Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 110:2858–2902.
17. Bartholomä MD (2012) Recent developments in the design of bifunctional chelators for metal-based radiotherapeutics used in positron emission imaging. Inorg Chim Acta 389:36–51.
18. Price SW, Ongville C (2014) Matching chelators to radionuclides for radiopharmaceuticals. Chem Soc Rev 43:260–290.
19. Kumar P, Tripathi S, Mehta N, Wickstrom E, Thakur M (2017) A preclinical evaluation of Ga-68 labeled NODAGA and DOTA peptide conjugates to image breast cancer. J Nucl Med 58:675.
20. Zhou Z, et al. (2018) Negative dendritic effect on enzymatic hydrolysis of dendrimer conjugates. Chem Commun (Camb) 54:5956–5959.
21. Liu X, et al. (2015) Promoting sRNA delivery via enhanced cellular uptake using an arginine-decorated amphiphilic dendrimer. Nanoscale 7:3867–3875.
22. Yu T, et al. (2012) An amphiphilic dendrimer for effective delivery of small interfering RNA and gene silencing in vitro and in vivo. Angew Chem Int Ed Engl 51:8478–8484.
23. Brevard C, Granger P (1981) Handbook of High Resolution Multinuclear NMR (Wiley, New York), pp 132–133.
24. Bogusz S, Venable RM, Pastor RW (2000) Molecular dynamics simulations of octyl glycoside micelles. J Phys Chem B 104:5462–5470.
25. Thornalley KA, Laurini E, Prid S, Smith DK (2018) Enantiomeric and diastereomeric self-assembled multivalent nanostructures: Understanding the effects of chirality on binding to polyanionic heparin and DNA. Angew Chem Int Ed Engl 57:8530–8534.
26. Kato T, Inui Y, Nakamura A, Ko T (2016) Brain fluorodeoxyglucose (FDG) PET in demyelinating. Ageing Res Rev 30:73–84.
27. Kim E, Kim J, Maelandmo GM, Johansen B, Moestue SA (2017) Anti-angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro-computed tomography angiography and dynamic contrast enhanced MRI. Magn Reson Imaging 53:104–113.
28. Viallard C, Larrivee B (2017) Tumor angiogenesis and vascular normalisation: Alternative native therapeutic targets. Angiogenes 20:409–426.
29. Hansen AE, et al. (2015) Positron emission tomography based elucidation of the enhanced permeability and retention effect in dogs with cancer using copper-64 liposomes. ACS Nano 9:6885–6905.
30. Ni D, et al. (2018) Radiolabeled polyoxometalate clusters: Kidney dysfunction evaluation and tumor diagnosis by positron emission tomography imaging. Biomaterials 171:145–152.
31. Lee H, et al. (2017) A new class of supramolecular dendrimers as efficient DC-targeting agents. Small 13:1200201.
32. Schluep T, et al. (2009) Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci USA 106:11394–11399.
33. Metzger AP, et al. (1998) Amphiphilic dendrimers as building blocks in supramolecular assemblies. J Am Chem Soc 120:8199–8208.
34. Filippi M, et al. (2014) Dendrimersomes: A new vesicular nano-platform for MR molecular imaging applications. Chem Commun (Camb) 50:3453–3456.
35. Filippi M, et al. (2015) Novel stable dendrimeresomes formulation for safe bioimaging applications. Nanoscale 7:12943–12954.